{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:41:30Z","timestamp":1792784490552,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"OncoQuest, Inc."}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.ygyno.2019.12.024","type":"journal-article","created":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T12:37:57Z","timestamp":1578314277000},"page":"523-529","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study"],"prefix":"10.1016","volume":"156","author":[{"given":"Molly","family":"Brewer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Angioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovani","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenica","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Terranova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi Benedetti","family":"Panici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Raspagliesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Scollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francessco","family":"Plotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Ferrandina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanda","family":"Salutari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Braly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Holloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Method","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madi","family":"Madiyalakan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliel","family":"Bayever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Nicodemus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2019.12.024_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2019.12.024_bb0015","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","article-title":"Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the gynecologic cancer intergroup","volume":"27","author":"Bookman","year":"2009","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.12.024_bb0020","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1200\/JCO.2018.36.15_suppl.5500","article-title":"Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III\/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602","volume":"36","author":"Onda","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.12.024_bb0025","doi-asserted-by":"crossref","first-page":"5518","DOI":"10.1200\/JCO.2018.36.15_suppl.5518","volume":"36","author":"Vergote","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.12.024_bb0030","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2019.12.024_bb0050","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2019.12.024_bb0055","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.12.024_bb0060","series-title":"Avelumab in Previously Untreated Patients with Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)","article-title":"Identifier NCT02718417","author":"ClinicalTrials.gov [Internet]","year":"2000"},{"key":"10.1016\/j.ygyno.2019.12.024_bb0065","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1200\/JCO.2008.17.8400","article-title":"Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer","volume":"27","author":"Berek","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.12.024_bb0070","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1200\/JCO.2012.46.4057","article-title":"Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO\u2013the MIMOSA study","volume":"31","author":"Sabbatini","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.12.024_bb0075","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/CJI.0b013e31818b3dad","article-title":"The immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer","volume":"32","author":"Braly","year":"2009","journal-title":"J. Immunother."},{"key":"10.1016\/j.ygyno.2019.12.024_bb0080","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the gynecological cancer intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2019.12.024_bb0085","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2019.12.024_bb0090","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1517\/14712598.7.3.331","article-title":"Role of monoclonal antibodies in tumor-specific immunity","volume":"7","author":"Nicodemus","year":"2007","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.ygyno.2019.12.024_bb0095","first-page":"142.13","article-title":"In vivo culture system to study chemo-immunotherapy synergy","volume":"176","author":"Schultes","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.ygyno.2019.12.024_bb0100","doi-asserted-by":"crossref","first-page":"8059","DOI":"10.1158\/0008-5472.CAN-05-1797","article-title":"Leveraging the activity of tumor vaccines with cytotoxic chemotherapy","volume":"65","author":"Emens","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2019.12.024_bb0105","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1182\/blood-2004-06-2410","article-title":"Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide","volume":"105","author":"Lutsiak","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ygyno.2019.12.024_bb0110","article-title":"Translational immune correlates of indirect antibody immunization using scheduled combination therapy with carboplatin\/paclitaxel plus oregovomab: a randomized phase II study","author":"Battaglia","year":"2019","journal-title":"Cancer Immunology and Immunotherapy"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819318451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819318451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:48:18Z","timestamp":1758772098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825819318451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0090825819318451"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.12.024","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737186538.793572794","asserted-by":"object"}]},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.12.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}